Bacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects
Open Access
- 19 February 2026
- journal article
- review article
- Published by Wiley in Advanced Science
- Vol. 13 (29) , e21684
Abstract
Cancer immunotherapy is increasingly moving toward personalized, precision‐based strategies, with cancer vaccines emerging as a promising approach to reshape treatment. However, despite their potential, current tumor vaccines often yield limited clinical responses and subpar immunogenicity, underscoring the urgent need for innovative delivery systems to enhance immune activation. Bacterial outer membrane vesicles (OMVs), which possess natural immunomodulatory properties and impressive engineering flexibility, have attracted attention as versatile platforms for vaccine development and bioengineering applications. This review thoroughly summarizes recent advances in using OMVs to enhance the effectiveness of cancer vaccines. First, we explain the key biological features of OMVs that support their immunotherapeutic potential. Next, we carefully analyze the primary mechanisms by which OMVs enhance immune responses, as well as cutting‐edge engineering strategies to improve their safety, immunogenicity, and specificity. Additionally, we discuss the significant challenges that hinder the clinical use of OMV‐based cancer vaccines and provide a comprehensive review of current progress and future outlooks. Looking forward, combining artificial intelligence, tumor microenvironment profiling, and neoantigen discovery is expected to drive the development of next‐generation, personalized OMV‐based immunotherapies. Overall, OMVs stand out as a transformative platform capable of overcoming major obstacles in cancer vaccine development and pushing forward future cancer immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (32222045)
- National Natural Science Foundation of China (32171384)
- National Natural Science Foundation of China (32471450)
- National Natural Science Foundation of China (82402462)
- Natural Science Foundation of Beijing Municipality (7244523)
This publication has 165 references indexed in Scilit:
- A Self‐Priming Pyroptosis‐Inducing Agent for Activating Anticancer ImmunityAdvanced Healthcare Materials, 2025
- Outer Membrane Vesicle‐Based Nanohybrids Target Tumor‐Associated Macrophages to Enhance Trained Immunity‐Related Vaccine‐Generated Antitumor ActivityAdvanced Materials, 2023
- Engineered Bacterial Outer Membrane Vesicles as Controllable Two‐Way Adaptors to Activate Macrophage Phagocytosis for Improved Tumor ImmunotherapyAdvanced Materials, 2022
- Rapid Surface Display of mRNA Antigens by Bacteria‐Derived Outer Membrane Vesicles for a Personalized Tumor VaccineAdvanced Materials, 2022
- Self‐Blockade of PD‐L1 with Bacteria‐Derived Outer‐Membrane Vesicle for Enhanced Cancer ImmunotherapyAdvanced Materials, 2021
- Engineered Bacteria Enhance Immunotherapy and Targeted Therapy through Stromal Remodeling of TumorsAdvanced Healthcare Materials, 2021
- Physical Disruption of Solid Tumors by Immunostimulatory Microrobots Enhances Antitumor ImmunityAdvanced Materials, 2021
- Biomineralized Bacterial Outer Membrane Vesicles Potentiate Safe and Efficient Tumor Microenvironment Reprogramming for Anticancer TherapyAdvanced Materials, 2020
- A Hybrid Eukaryotic–Prokaryotic Nanoplatform with Photothermal Modality for Enhanced Antitumor VaccinationAdvanced Materials, 2020
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy DrugsJAMA Network Open, 2019